Reuters logo
BRIEF-Shilpa Medicare Gets 483 Observations From U.S. FDA For SEZ Formulation Facilities In Telangana
December 5, 2017 / 10:40 AM / in 9 days

BRIEF-Shilpa Medicare Gets 483 Observations From U.S. FDA For SEZ Formulation Facilities In Telangana

Dec 5 (Reuters) - Shilpa Medicare Ltd:

* SAYS GOT 483 OBSERVATIONS FROM U.S. FDA IN RELATION TO SEZ FORMULATION FACILITIES SITUATED AT JADCHERLA, TELANGANA

* SAYS TOTAL 10 OBSERVATIONS WERE CITED DURING CLOSE UP MEETING

* SAYS 7 OBSERVATIONS ARE IMPROVEMENT IN PROCEDURES AND PRACTICES

* SAYS 3 OBSERVATIONS RELATED TO SETTING OF ANALYTICAL SPECIFICATIONS, TEST PROCEDURES, METHOD VALIDATION Source text - bit.ly/2BIazzH Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below